跳至主導覽
跳至搜尋
跳過主要內容
長庚大學學術能量集萃 首頁
說明與常見問題
English
中文
首頁
學者概覽
研究單位
研究產出
研究計畫-專案
獎項
活動
按專業知識、姓名或所屬機構搜尋
查看斯高帕斯 (Scopus) 概要
陳 怡婷
教授
,
生物醫學系(含學士班、臨床試驗與評估碩士班)
https://orcid.org/0000-0002-0063-4965
電子郵件
D000009985
cgu.edu
tw
h-index
h10-index
h5-index
2428
引文
29
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1113
引文
20
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
237
引文
8
h-指數
按照存儲在普爾（Pure）的出版物數量及斯高帕斯（Scopus）引文計算。
1998 …
2024
每年研究產出
概覽
指紋
網絡
研究計畫-專案
(17)
研究產出
(116)
相近領域學者
(6)
指導學生論文
(13)
指紋
查看啟用 Yi-Ting Chen 的研究主題。這些主題標籤來自此人的作品。共同形成了獨特的指紋。
排序方式
重量
按字母排序
Biochemistry, Genetics and Molecular Biology
Protein
100%
Sample
75%
Mass Spectrometry
43%
Proteomics
37%
Metabolite
37%
Development
29%
Metabolomics
28%
Peptide
19%
Antibody
19%
Proteome
17%
Urine Sampling
15%
Time
14%
Isotope Labeling
12%
Liquid Chromatography-Mass Spectrometry
11%
Metabolome
11%
Apolipoprotein
10%
MMP1
10%
Bladder Potential
10%
Liquid
9%
Apolipoprotein A2
9%
Surface Property
9%
Magnetism
9%
Quantitative Proteomics
9%
Protein Urine Level
9%
Prostate-Specific Antigen
9%
Association
9%
Biomarker Discovery
9%
Biological Activity
8%
Tandem Mass Spectrometry
8%
Comprehension
8%
Metabolic Pathway
7%
Isobaric Tag for Relative and Absolute Quantitation
7%
Precursor
7%
Cancer Cell
7%
Molecule
7%
Cancer Screening
6%
Age
6%
Liquid Chromatography
6%
Peroxiredoxin
5%
Mouse
5%
Transcriptome
5%
Histidine
5%
Transcriptomics
5%
Taxonomy
5%
Antibody Affinity
5%
Solution and Solubility
5%
Quantitative Technique
5%
Medicine and Dentistry
Patient
68%
Inpatient
34%
Bladder Cancer
33%
Biological Marker
32%
Urinary System
30%
Malignant Neoplasm
24%
Acute Kidney Injury
23%
Therapeutic Procedure
23%
Diagnosis
19%
Protein
19%
Bladder
16%
Cells
15%
Kidney Transplantation
14%
Prostate Cancer
12%
Serum
12%
Urine
12%
Analysis
12%
Transurethral Resection
11%
Transitional Cell Carcinoma
11%
Upper Urinary Tract
11%
Prostate Specific Antigen
11%
Cancer Diagnosis
11%
Recurrent Disease
11%
Age
10%
Follow up
10%
Neutrophil
10%
Tumor Marker
10%
Proteomics
9%
Disease
9%
Polypeptide
9%
Cancer Prognosis
9%
Mouth Squamous Cell Carcinoma
9%
Metabolomics
9%
Heart Surgery
9%
Combination Therapy
9%
Headache
9%
Parathyroidectomy
9%
Neoplasm
8%
Neutrophil Gelatinase Associated Lipocalin
8%
Incidence
8%
Multiple Reaction Monitoring
8%
Calgranulin
7%
Cancer Cell
7%
Prostate Hypertrophy
7%
Hernia
7%
Diabetes Mellitus
7%
Kidney
6%
Mass Spectrum
6%
Diagnostic Performance
6%
Coronary Care Unit
6%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
17%
Bladder Cancer
15%
Protein
14%
Diabetes Mellitus
11%
Diseases
11%
Acute Kidney Failure
9%
Prostate Specific Antigen
9%
Polyglactin
9%
Wound
9%
Prostate Cancer
8%
Organic Solvent
7%
Incidence
6%
Transitional Cell Carcinoma
6%
Stable Isotope
6%
Malignant Neoplasm
6%
Drug
5%
Platelet Derived Growth Factor
5%
Neoplasm
5%
Inflammation
5%
Tacrolimus
5%
Antibody
5%
